Human Genome Epidemiology Literature Finder
Records 1 - 29 (of 29 Records) |
Query Trace: Nausea and EGFR[original query] |
---|
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational new drugs 2012 Jun 30 (3): 1164-74. Oh Do-Youn, Lee Keun Wook, Lee Kyung-Hee, Sohn Chang-Hak, Park Young Suk, Zang Dae Young, Ryoo Hun-Mo, Song Hong-Suk, Kim Jin-Soo, Kang Hye-Jin, Kim Bong-Seog, Bang Yung-J |
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 1 17 (5): 1131-9. Jänne Pasi A, Boss David S, Camidge D Ross, Britten Carolyn D, Engelman Jeffrey A, Garon Edward B, Guo Feng, Wong Steven, Liang Jane, Letrent Stephen, Millham Robert, Taylor Ian, Eckhardt S Gail, Schellens Jan H |
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012 May 7 (5): 856-65. Pietanza M Catherine, Gadgeel Shirish M, Dowlati Afshin, Lynch Thomas J, Salgia Ravi, Rowland Kendrith M, Wertheim Michael S, Price Katharine A, Riely Gregory J, Azzoli Christopher G, Miller Vincent A, Krug Lee M, Kris Mark G, Beumer Jan H, Tonda Margaret, Mitchell Ben, Rizvi Naiyer |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Sep 31 (27): 3327-34. Sequist Lecia V, Yang James Chih-Hsin, Yamamoto Nobuyuki, O'Byrne Kenneth, Hirsh Vera, Mok Tony, Geater Sarayut Lucien, Orlov Sergey, Tsai Chun-Ming, Boyer Michael, Su Wu-Chou, Bennouna Jaafar, Kato Terufumi, Gorbunova Vera, Lee Ki Hyeong, Shah Riyaz, Massey Dan, Zazulina Victoria, Shahidi Mehdi, Schuler Mart |
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. OncoTargets and therapy 2013 6 803-9. Kader Yasser Abdel, Le Chevalier Thierry, El-Nahas Tamer, Sakr A |
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jun 19 (11): 3068-77. Socinski Mark A, Goldman Jonathan, El-Hariry Iman, Koczywas Marianna, Vukovic Vojo, Horn Leora, Paschold Eugene, Salgia Ravi, West Howard, Sequist Lecia V, Bonomi Philip, Brahmer Julie, Chen Lin-Chi, Sandler Alan, Belani Chandra P, Webb Timothy, Harper Harry, Huberman Mark, Ramalingam Suresh, Wong Kwok-Kin, Teofilovici Florentina, Guo Wei, Shapiro Geoffrey |
Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Targeted oncology 2015 Jun . Guetz Gaetan Des, Landre Thierry, Uzzan Bernard, Chouahnia Kader, Nicolas Patrick, Morere Jean-Franço |
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Annals of oncology : official journal of the European Society for Medical Oncology 2015 1 26 (5): 998-1005. Wong A L, Soo R A, Tan D S, Lee S C, Lim J S, Marban P C, Kong L R, Lee Y J, Wang L Z, Thuya W L, Soong R, Yee M Q, Chin T M, Cordero M T, Asuncion B R, Pang B, Pervaiz S, Hirpara J L, Sinha A, Xu W W, Yuasa M, Tsunoda T, Motoyama M, Yamauchi T, Goh B |
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Annals of oncology : official journal of the European Society for Medical Oncology 2017 9 28 (10): 2443-2450. Shi Y K, Wang L, Han B H, Li W, Yu P, Liu Y P, Ding C M, Song X, Ma Z Y, Ren X L, Feng J F, Zhang H L, Chen G Y, Han X H, Wu N, Yao C, Song Y, Zhang S C, Song W, Liu X Q, Zhao S J, Lin Y C, Ye X Q, Li K, Shu Y Q, Ding L M, Tan F L, Sun |
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 04 13 (4): 576-584. Felip Enriqueta, Barlesi Fabrice, Besse Benjamin, Chu Quincy, Gandhi Leena, Kim Sang-We, Carcereny Enric, Sequist Lecia V, Brunsvig Paal, Chouaid Christos, Smit Egbert F, Groen Harry J M, Kim Dong-Wan, Park Keunchil, Avsar Emin, Szpakowski Sebastian, Akimov Mikhail, Garon Edward |
Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations. Investigational new drugs 2017 11 36 (4): 608-614. Tamiya Motohiro, Tamiya Akihiro, Shiroyama Takayuki, Takeoka Sawa, Naito Yujiro, Omachi Naoki, Kimura Yohei, Morishita Naoko, Suzuki Hidekazu, Okamoto Norio, Okishio Kyoichi, Kawaguchi Tomoya, Atagi Shinji, Hirashima Tomono |
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma. Clinical lung cancer 2018 8 19 (5): e775-e781. Oh In-Jae, Hur Jae Young, Park Cheol-Kyu, Kim Young-Chul, Kim Seung Joon, Lee Min Ki, Kim Hee Joung, Lee Kye Young, Lee Jae Cheol, Choi Chang-M |
A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations. Medical oncology (Northwood, London, England) 2018 2 35 (3): 34. Tanaka Hisashi, Taima Kageaki, Tanaka Yoshihito, Itoga Masamichi, Ishioka Yoshiko, Nakagawa Hideyuki, Baba Keisuke, Hasegawa Yukihiro, Takanashi Shingo, Tasaka Sadato |
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC cancer 2018 Dec 18 (1): 1231. Tsutani Yasuhiro, Miyata Yoshihiro, Masuda Takeshi, Fujitaka Kazunori, Doi Mihoko, Awaya Yoshikazu, Kuyama Shoichi, Kitaguchi Soichi, Ueda Kazuhiro, Hattori Noboru, Okada Morihi |
Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study. Clinical lung cancer 2018 11 19 (6): 484-492. Xie Hounai, Wang Hui, Xu Lin, Li Meng, Peng Yue, Cai Xianyun, Feng Zhen, Ren Wangang, Peng Zhongm |
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC cancer 2019 Jun 19 (1): 595. Fang Wenfeng, Huang Yihua, Hong Shaodong, Zhang Zhonghan, Wang Minghui, Gan Jiadi, Wang Wenjing, Guo Honglin, Wang Kai, Zhang |
The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis. Pathology oncology research : POR 2019 6 26 (2): 1137-1143. Zhang Lei, Ren Hong-Wei, Wu Qi-Long, Wu Yan-Juan, Song Xia |
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study. Journal of translational medicine 2019 2 17 (1): 52. Wang Wenxian, Wang Hong, Lu Peihua, Yu Zongyang, Xu Chunwei, Zhuang Wu, Song Zheng |
Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases. Oncology research 2019 Oct . Xu Jianping, Liu Xiaoyan, Yang Sheng, Shi Yuank |
Erlotinib and bevacizumab in elderly patients ?75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Investigational new drugs 2020 Aug . Aoshima Yoichiro, Karayama Masato, Inui Naoki, Yasui Hideki, Hozumi Hironao, Suzuki Yuzo, Furuhashi Kazuki, Fujisawa Tomoyuki, Enomoto Noriyuki, Nakamura Yutaro, Mikamo Masashi, Matsuura Shun, Kusagaya Hideki, Kaida Yusuke, Uto Tomohiro, Hashimoto Dai, Matsui Takashi, Asada Kazuhiro, Suda Takafu |
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. Targeted oncology 2021 5 16 (3): 339-355. Yoh Kiyotaka, Hirashima Tomonori, Saka Hideo, Kurata Takayasu, Ohe Yuichiro, Hida Toyoaki, Mellemgaard Anders, Verheijen Remy B, Ou Xiaoling, Ahmed Ghada F, Hayama Manabu, Sugibayashi Ko, Oxnard Geoffrey |
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. JCO precision oncology 2021 5 1 . McCoach Caroline E, Yu Aiming, Gandara David R, Riess Jonathan W, Vang Daniel P, Li Tiahong, Lara Primo N, Gubens Matthew, Lara Frances, Mack Philip C, Beckett Laurel A, Kelly Kar |
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer discovery 2021 2 11 (7): 1688-1699. Riely Gregory J, Neal Joel W, Camidge D Ross, Spira Alexander I, Piotrowska Zofia, Costa Daniel B, Tsao Anne S, Patel Jyoti D, Gadgeel Shirish M, Bazhenova Lyudmila, Zhu Viola W, West Howard L, Mekhail Tarek, Gentzler Ryan D, Nguyen Danny, Vincent Sylvie, Zhang Steven, Lin Jianchang, Bunn Veronica, Jin Shu, Li Shuanglian, Jänne Pasi |
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 9 29 (3): 508-512. Duke Elizabeth S, Stapleford Liza, Drezner Nicole, Amatya Anup K, Mishra-Kalyani Pallavi S, Shen Yuan-Li, Maxfield Kimberly, Zirkelbach Jeanne Fourie, Bi Youwei, Liu Jiang, Zhang Xinyuan, Wang Hezhen, Yang Yuching, Zheng Nan, Reece Kelie, Wearne Emily, Glen Jacqueline J, Ojofeitimi Idara, Scepura Barbara, Nair Abhilasha, Bikkavilli Rama Kamesh, Ghosh Soma, Philip Reena, Pazdur Richard, Beaver Julia A, Singh Harpreet, Donoghue Mart |
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO open 2022 6 7 (3): 100506. Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini |
Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study. ESMO open 2022 5 7 (3): 100473. Xing P, Zheng X, Wang Y, Chu T, Wang S, Jiang J, Qian J, Han X, Ding L, Wang Y, Cui L, Li H, Li L, Chen X, Han B, Hu P, Shi |
RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer. Biomedicines 2023 5 11 (5): . Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouz |
A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
Predictive Value of EGFR Mutation Status for First-Line Tyrosine Kinase Inhibitor Treatment in Patients with Advanced Lung Cancer. Alternative therapies in health and medicine 2023 12 . Youqin Xie, Jinliang Chen, Wen Zhu, Zhihui Ye, Xuedong |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: